Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Niagen Bioscience (NAGE) over the last 13 years, with Q3 2025 value amounting to $2.7 million.

  • Niagen Bioscience's Non-Current Deffered Revenue rose 368.36% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 368.36%. This contributed to the annual value of $2.6 million for FY2024, which is 2210.81% down from last year.
  • As of Q3 2025, Niagen Bioscience's Non-Current Deffered Revenue stood at $2.7 million, which was up 368.36% from $2.7 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Non-Current Deffered Revenue high stood at $4.4 million for Q2 2021, and its period low was $2.6 million during Q3 2024.
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $3.8 million (2023), whereas its average is $3.6 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first soared by 1625.65% in 2021, then crashed by 3223.86% in 2024.
  • Over the past 5 years, Niagen Bioscience's Non-Current Deffered Revenue (Quarter) stood at $4.3 million in 2021, then decreased by 7.96% to $4.0 million in 2022, then dropped by 17.22% to $3.3 million in 2023, then fell by 22.11% to $2.6 million in 2024, then increased by 3.68% to $2.7 million in 2025.
  • Its Non-Current Deffered Revenue was $2.7 million in Q3 2025, compared to $2.7 million in Q2 2025 and $2.6 million in Q1 2025.